Semaglutide injection: how long does it take to work?

What the trial data tells us about timing

The STEP 1 trial, published in the New England Journal of Medicine, is the foundational evidence for semaglutide 2.4mg (Wegovy) in weight management. Participants who received semaglutide lost roughly 15% of their body weight over 68 weeks, compared with around 2.4% in the placebo group. That headline figure, though, obscures something important about timing: weight loss in the trial did not arrive in a rush at the beginning. It built progressively, tracking closely with dose escalation. The titration schedule starts at 0.25mg and increases in steps roughly every four weeks, with the body adapting to each level before the next. Most of the measurable loss accumulated in the middle and later phases of treatment, once participants were established on higher doses. Early weeks are more about tolerability than transformation. Nausea, if it occurs, tends to be most noticeable at dose increases and generally eases within a week or two as the body adjusts. That pattern is consistent across the NHS semaglutide medicines guidance, which notes that gastrointestinal effects are common at the start and usually settle over time.

The first few weeks: what is actually changing

The appetite-reducing effect tends to arrive ahead of visible weight change. GLP-1 receptor agonists like semaglutide slow gastric emptying, which means food stays in the stomach longer. Meals feel filling sooner, and the urge to snack between them decreases. Many people notice this shift in hunger signals in the first week or two, and if you are curious about how long after each Wegovy injection these effects typically begin to show up, that page walks through the timing in detail. The scales, understandably, take longer to reflect it. A few pounds in the first fortnight is plausible; a stone inside a month is not a realistic expectation. If you want to understand the mechanism behind this early appetite change in more detail, the full explanation of how semaglutide works at a biological level covers the GLP-1 pathway clearly. One practical note worth raising: the first pen that arrives (in plain packaging via DPD, tracked to your door) contains the 0.25mg starting dose. Its job is to introduce your system to the medicine gently. Significant appetite suppression usually becomes more pronounced as the dose increases over the following months.

Why responses differ from person to person

Two people can start semaglutide on the same day and report quite different experiences at week eight. That is not a sign that one of them is doing something wrong. Starting weight, metabolic rate, how closely diet and activity patterns shift alongside treatment, and individual variation in GLP-1 receptor sensitivity all play a role. Clinical guidance does include a practical checkpoint: if less than 5% of body weight has been lost after six months at the maintenance dose, a prescriber would typically review whether to continue. This threshold is reflected in NICE's appraisal of semaglutide for weight management (TA875). It is worth keeping in mind that semaglutide is licensed as an adjunct to a reduced-calorie diet and increased physical activity, the medicine works alongside those changes, not independently of them. For more on what to expect in the hours immediately after each injection, this page looks specifically at the short-term window after dosing. And if you are weighing up what private treatment typically costs in the UK, that page sets out the honest market picture without the headline-rate omissions. Semaglutide is available in the UK as Wegovy; Ozempic is also semaglutide but licensed for type 2 diabetes, not weight loss, an important distinction that causes real confusion.

Patience, consistency, and what to do if progress stalls

The slow-build nature of treatment is not a flaw in the design. It reflects how weight regulation works physiologically, and the titration schedule exists specifically to reduce side effects while allowing the body to adapt. A stall at a lower dose is common and does not mean treatment has failed; it often means the therapeutic dose has not yet been reached. If appetite suppression feels minimal or weight is not shifting after several months at the maintenance dose, that is a conversation to have with a prescriber rather than a reason to stop. Self-adjusting the dose or timing of injections is not something to do based on online guidance, the prescriber and the Patient Information Leaflet are the right sources for any changes. For a clear walkthrough of the full injection process, the step-by-step guide to taking semaglutide correctly is a useful practical reference. If any of this has prompted questions about whether semaglutide might be suitable for you, speaking to our prescribers is the natural next step. A clinical assessment is the only way to know whether treatment is appropriate for your circumstances.